Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY4170156 + bevacizumab
- Development stage
- Phase 3
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
LY4170156 + bevacizumab is a combination investigational regimen being studied for advanced solid tumors in a multi-part Phase 1 trial. LY4170156 is an experimental agent (molecular class and precise target undisclosed in available sources) developed by Eli Lilly and Company, while bevacizumab is an approved monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis. This combination is administered intravenously and aims to evaluate safety, tolerability, and preliminary anti-tumor activity, including progression free survival, overall response rate, and other clinical endpoints in ovarian, endometrial, colorectal, cervical, pancreatic, non-small cell lung, and triple-negative breast cancers[1][2][4].
- Other names
- LY4170156 + bevacizumab
02
Targets
FOLR1 (FRα)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on LY4170156 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY4170156 + bevacizumab.